Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

Novavax (NVAX) announced positive initial results from a late-stage study of its COVID-19-influenza combination (CIC) vaccine, demonstrating robust immune responses in adults aged 65 and older, comparable to its approved COVID-19 vaccine, Nuvaxovid, and Sanofi's Fluzone HD. The company intends to use these results to design another late-stage trial to support potential regulatory submissions, while also seeking strategic collaborations to fund further development and commercialization. This announcement follows the recent FDA approval of Nuvaxovid, albeit with a narrower label than expected, and Sanofi's acquisition of exclusive global marketing rights for the vaccine, excluding certain territories.

Analysis

Novavax (NVAX) has reported encouraging preliminary immunogenicity data from an initial cohort in a late-stage study of its COVID-19-influenza combination (CIC) vaccine and a stand-alone influenza candidate, showing robust immune responses in adults aged 65 and older across three flu strains (H1N1, H3N2, B) and the SARS-CoV-2 strain. These responses were reportedly similar to those generated by its approved Nuvaxovid COVID-19 vaccine and Sanofi's (SNY) Fluzone HD influenza vaccine. However, Novavax emphasized this study was not designed for statistical significance and these findings will guide the design of a subsequent late-stage trial intended to support regulatory submissions. Concurrently, Novavax is actively seeking strategic collaborations to finance the further development and commercialization of these candidates, reflecting a strategic shift towards partnerships. This development follows the recent FDA approval of Nuvaxovid, which, while positive, came with a narrower label than initially anticipated, granting full approval for adults 65+ but restricting use in individuals aged 12-64 to those with high-risk underlying conditions. Sanofi has secured exclusive global marketing rights for Nuvaxovid (excluding certain territories), with Novavax eligible for tiered royalties. Despite these positive steps, NVAX shares have underperformed the industry year-to-date. The competitive landscape for COVID-flu combination shots includes Pfizer (PFE) and Moderna (MRNA), both of whom have faced recent development challenges: Moderna voluntarily withdrew its FDA filing for mRNA-1083 to provide additional flu efficacy data, while Pfizer's phase III study missed a primary immunogenicity objective. Sanofi is also advancing its own combination candidates, leveraging Nuvaxovid, with two receiving FDA fast-track designation.

Key Decisions for Investors

• Investors should monitor Novavax's ability to secure strategic partnerships to fund the next phase of its CIC vaccine development, as this is crucial for its progression to potential regulatory submission and commercialization.
• The narrower-than-expected FDA label for Nuvaxovid and the stock's year-to-date underperformance warrant careful consideration, weighing the potential of the CIC vaccine against existing commercial and execution risks.
• Given the competitive landscape, where rivals like Moderna and Pfizer have encountered setbacks, Novavax's progress with its CIC candidate should be closely watched, alongside Sanofi's efforts to commercialize Nuvaxovid and develop its own combination vaccines utilizing Novavax's technology.